News & Updates

Show Multimedia Only
Tarlatamab – a new SoC in 2L SCLC

Tarlatamab – a new SoC in 2L SCLC

9 hours ago byMIMS Editorial Team

After decades of topotecan being the sole standard second-line (2L) treatment for small-cell lung cancer (SCLC) in most countries, tarlatamab’s efficacy and a favourable safety and tolerability profile vs chemotherapy (CT) have defined a new standard of care (SoC) for patients whose disease progressed on or after initial platinum-based CT, according to Dr Martin Wermke of the National Center for Tumor Diseases Dresden Early Clinical Trial Unit in Dresden, Germany, who spoke at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

9 hours ago
Personalized mRNA cancer vaccine + pembrolizumab hits targets in phase III melanoma trial

Personalized mRNA cancer vaccine + pembrolizumab hits targets in phase III melanoma trial

10 Nov 2026 byAudrey Abella

In the large phase III INTerpath-001 study evaluating individuals with resected stage IIB–IV melanoma, recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) improved when the mRNA-based individualized neoantigen therapy intismeran autogene was added to pembrolizumab compared with pembrolizumab alone.

10 Nov 2026